Moreover, a lower protein level of Y397-FAK phosphorylation was found in paclitaxel combined with BI853520 treatment group than in the BI853520 or paclitaxel monotherapy group (Fig. 8C, D), which is consistent with our results in vitro, that BI853520 improves the sensitivity to chemotherapy of ovarian cancer cells. This evidence concerns the gene PTK2 and ovarian cancer.